Q-omics provides the consensus-scored RAPGEF6 profile across patient tissues and cancer cell-line models. RAPGEF6 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAPGEF6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RAPGEF6 RNA expression shows 20,899 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where RAPGEF6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAPGEF6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAPGEF6 survival associations across molecular data types. RAPGEF6 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAPGEF6 RNA expression–survival associations across cancer types. High RAPGEF6 expression shows unfavorable associations in KIRP, UVM, KICH, HNSC and OV, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAPGEF6 RNA expression.
This table summarizes RAPGEF6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAPGEF6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAPGEF6 shows lower tumor expression in LUSC and higher tumor expression in KIRC, LIHC, KIRP, STAD and BRCA. The KIRC box plot shows higher RAPGEF6 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with RAPGEF6 in patient tissues and cancer cell lines. In patient samples, RAPGEF6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAPGEF6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
